Aptamers as radiopharmaceuticals for nuclear imaging and therapy

Research output: Contribution to journalArticlepeer-review

Standard

Aptamers as radiopharmaceuticals for nuclear imaging and therapy. / Gijs, Marlies; Aerts, An; Impens, Nathalie; Baatout, Sarah; Luxen, André.

In: Nuclear Medicine and Biology, 15.04.2016.

Research output: Contribution to journalArticlepeer-review

Author

Bibtex - Download

@article{1cfa002003924c1d80eebc62c4c917a4,
title = "Aptamers as radiopharmaceuticals for nuclear imaging and therapy",
abstract = "Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production,modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers.",
keywords = "Aptamers, radiopharmaceuticals, nuclear imaging, therapy",
author = "Marlies Gijs and An Aerts and Nathalie Impens and Sarah Baatout and Andr{\'e} Luxen",
note = "SCORE=10",
year = "2016",
month = apr,
day = "15",
doi = "10.1016/j.nucmedbio.2015.09.005",
language = "English",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier",

}

RIS - Download

TY - JOUR

T1 - Aptamers as radiopharmaceuticals for nuclear imaging and therapy

AU - Gijs, Marlies

AU - Aerts, An

AU - Impens, Nathalie

AU - Baatout, Sarah

AU - Luxen, André

N1 - SCORE=10

PY - 2016/4/15

Y1 - 2016/4/15

N2 - Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production,modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers.

AB - Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production,modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers.

KW - Aptamers

KW - radiopharmaceuticals

KW - nuclear imaging

KW - therapy

UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/20890377

U2 - 10.1016/j.nucmedbio.2015.09.005

DO - 10.1016/j.nucmedbio.2015.09.005

M3 - Article

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

ER -

ID: 1916056